042520.KQ - HansBiomed Corporation

KOSDAQ - KOSDAQ Delayed Price. Currency in KRW

HansBiomed Corporation

64, Yuseong-daero
1628 beon-gil Yuseong-gu Daejeon
Seoul
South Korea
82 2 466 2266
http://www.hansbiomed.com

Sector
Industry
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Seok-Bae OhChief Financial Officer and Managing DirectorN/AN/A1971
Mr. Won-Gyun KwonSr. MD & DirectorN/AN/A1954
Mr. Ho-Chan HwangCEO & DirectorN/AN/A1958
Amounts are as of December 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

HansBiomed Corporation develops, produces, and sells medical materials and ingredients in South Korea and internationally. It offers bone and skin transplant tissue for dentistry, orthopedic/neurosurgery, and skin burn applications; and silicone polymer products, such as BellaGel breast implants, and ScarClinic silicone gel sheet for scar prevention and treatment, as well as forehead, malar, nasal, paranasal, chin, temple, and nostril facial implants. The company also provides medical devices, including Mint Lift, a non-surgical thread for face lifting; and Lion HT/HN, a hair transplanter body/needle. In addition, it offers bio technology products, such as self-skin cell treatment agents and pharmacological agent impregnated bone fillers. The company was formerly known as Hans Medical Corp. and changed its name to HansBiomed Corporation in June 2000. HansBiomed Corporation was founded in 1993 and is based in Seoul, South Korea.

Corporate Governance

HansBiomed Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.